Finally, we show that this previously unknown weakness of the HRAS gene points to a new mechanism for knocking out oncogenic HRAS by employing SSOs that block binding of the required splicing regulatory factors, resulting in exon 2 skipping and decreased growth of cancer cells. This evidence concerns the gene HRAS and cancer.